Selecting patients for treatment with ⁹⁰Y ibritumomab tiuxetan (Zevalin)GREGORY, Stephanie A.Seminars in oncology. 2003, Vol 30, Num 6, pp 17-22, issn 0093-7754, 6 p., SUP17Article

Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)GORDON, Leo I.Seminars in oncology. 2003, Vol 30, Num 6, pp 23-28, issn 0093-7754, 6 p., SUP17Article

La radio-immunothérapie des cancers = Radioimmunotherapy of cancersLEVEQUE, D; MONTEIRO, M.-C; DETOUR, J et al.Journal de pharmacie clinique (Paris). 2005, Vol 24, Num 3, pp 139-144, issn 0291-1981, 6 p.Article

Consensus Conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of HematologyVITOLO, Umberto; BAROSI, Giovanni; FANTI, Stefano et al.American journal of hematology. 2010, Vol 85, Num 2, pp 147-155, issn 0361-8609, 9 p.Article

Radiobiology of radioimmunotherapy with ⁹⁰Y ibritumomab tiuxetan (Zevalin)HERNANDEZ, M. Carmen; KNOX, Susan J.Seminars in oncology. 2003, Vol 30, Num 6, pp 6-10, issn 0093-7754, 5 p., SUP17Article

Report of a European consensus workshop to develop recommendations for the optimal use of ⁹⁰Y-ibritumomab tiuxetan (Zevalin®) in lymphomaHAGENBEEK, A; LEWINGTON, V.Annals of oncology. 2005, Vol 16, Num 5, pp 786-792, issn 0923-7534, 7 p.Article

Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndromeTSIMBERIDOU, Apostolia-Maria; MURRAY, James L; O'BRIEN, Susan et al.Cancer. 2004, Vol 100, Num 10, pp 2195-2200, issn 0008-543X, 6 p.Article

LES ANTICORPS MONOCLONAUX EN HÉMATOLOGIE EN 2009 = MONOCLONAL ANTIBODIES IN HEMATOLOGY IN 2009BONNET, C; BEGUIN, Y; DE PRIJCK, B et al.RMLG. Revue médicale de Liège. 2009, Vol 64, Num 5-6, pp 268-273, issn 0370-629X, 6 p.Article

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapyWISEMAN, Gregory A; LEIGH, Bryan R; DUNN, William L et al.Cancer biotherapy & radiopharmaceuticals. 2003, Vol 18, Num 2, pp 253-258, issn 1084-9785, 6 p.Article

Ibritumomab ^(Zevalin°): Concept séduisant, réalité décevante = Ibritumomab (Zevalin) Attracting concept, disappointing realityLa Revue Prescrire. 2005, Vol 25, Num 260, pp 259-262, issn 0247-7750, 4 p.Article

Efficacy and safety of ⁹⁰Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphomaWITZIG, Thomas E.Seminars in oncology. 2003, Vol 30, Num 6, pp 11-16, issn 0093-7754, 6 p., SUP17Article

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphomaWITZIG, Thomas E; FLINN, Ian W; WHITE, Christine A et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3262-3269, issn 0732-183XArticle

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaWISEMAN, Gregory A; LEIGH, Bryan R; WHITE, Christine A et al.Cancer biotherapy & radiopharmaceuticals. 2003, Vol 18, Num 2, pp 165-178, issn 1084-9785, 14 p.Article

Radiation dosimetry results and safety correlations from ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trialsWISEMAN, Gregory A; KORNMEHL, Ellen; LEIGH, Bryan et al.The Journal of nuclear medicine (1978). 2003, Vol 44, Num 3, pp 465-474, issn 0161-5505, 10 p.Article

Assessment of Metabolic Response to Radioimmunotherapy with ⁹⁰Y-Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaSTORTO, Giovanni; DE RENZO, Amalia; PACE, Leonardo et al.Radiology. 2010, Vol 254, Num 1, pp 245-252, issn 0033-8419, 8 p.Article

Japanese phase II study of ⁹⁰Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphomaTOBINAI, Kensei; WATANABE, Takashi; OKUMURA, Hirokazu et al.Cancer science. 2009, Vol 100, Num 1, pp 158-164, issn 1347-9032, 7 p.Article

Development of radioimmunotherapy for the treatment of non-Hodgkin's lymphoma : Monoclonal Antibody Therapy for B-Cell lymphomaMULTANI, P.International journal of hematology. 2002, Vol 76, Num 5, pp 401-410, issn 0925-5710, 10 p.Article

A Phase 2 Study of Yttrium-90 Ibritumomab Tiuxetan (Zevalin) in Patients With Chronic Lymphocytic LeukemiaJAIN, Nitin; WIERDA, William; FERRAJOLI, Alessandra et al.Cancer. 2009, Vol 115, Num 19, pp 4533-4539, issn 0008-543X, 7 p.Article

Radioimmunotherapy for treatment of b-cell lymphomas and other hematologic malignanciesPARK, Steven I; PRESS, Oliver W.Current opinion in hematology. 2007, Vol 14, Num 6, pp 632-638, issn 1065-6251, 7 p.Article

Radiation dose measurements for personnel performing ⁹⁰Y- ibritumomab tiuxetan administration: a comparison between two injection methods for dose reductionLAW, M; LIU, R; NG, S et al.British journal of radiology. 2009, Vol 82, Num 978, pp 491-496, issn 0007-1285, 6 p.Article

Arming antibodies : prospects and challenges for immunoconjugates : Antibody engineering and manufactureWU, Anna M; SENTER, Peter D.Nature biotechnology. 2005, Vol 23, Num 9, pp 1137-1146, issn 1087-0156, 10 p.Article

Full-dose ⁹⁰Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapyJACOBS, Samuel A; VIDNOVIC, Nicholas; JOYCE, Judith et al.Clinical cancer research. 2005, Vol 11, Num 19, pp 7146s-7150s, issn 1078-0432, 2Conference Paper

Ibritumomab : Atteintes cutanées graves = Ibritumonab : severe cutaneous adverse effectsLa Revue Prescrire. 2006, Vol 26, Num 268, issn 0247-7750, p. 25Article

Monoclonal antibody therapy for B-cell lymphoma : Monoclonal Antibody Therapy for B-Cell lymphomaGRILLO-LOPEZ, Antonio J.International journal of hematology. 2002, Vol 76, Num 5, pp 385-393, issn 0925-5710, 9 p.Article

Ibritumomab tiuxetan (Zevalin) contre les lymphomes non hodgkiniens = Ibritumonab tiuxetan (Zevalin) for non hodgkin lymphomasThe Medical letter on drugs and therapeutics (Edition française). 2002, Vol 24, Num 26, pp 113-114, issn 0253-8512, 2 p.Article